Shares of Tvardi Therapeutics (NASDAQ: TVRD) experienced a sharp rally on Tuesday, climbing nearly 40% in early afternoon trading following the release of Phase 1 clinical data for its novel STAT3 inhibitor prodrug, TTI-109. The stock reached an intraday high of $3.80 before settling at $2.81, representing a gain of 39.8% from the previous close of $2.01. Trading volume was exceptionally heavy, with approximately 53.9 million shares changing hands by early afternoon, equivalent to 5.7 times the company's total outstanding shares of 9.38 million as reported in its latest quarterly filing.
The surge in Tvardi's stock price brought its market capitalization to $26.3 million, a modest premium over the $25.0 million in cash and short-term investments the company reported as of March 31. Prior to the data release, the stock had been trading below its cash value, with an equity value of just $18.9 million at Monday's close. This valuation gap highlighted the market's skepticism about the company's prospects before the latest clinical readout.
The Phase 1 study evaluated TTI-109, a phosphate prodrug of Tvardi's earlier candidate TTI-101, in healthy volunteers. Key findings included rapid conversion of TTI-109 to TTI-101 within two hours, dose-proportional exposure, and near-identical plasma levels at molar-equivalent doses. Importantly, the study showed a significant improvement in tolerability: the duration of diarrhea, a common side effect, was reduced to 0.46 days for TTI-109, compared to 3.35 days for TTI-101 at near-equivalent doses. The 21-day repeat dosing regimen maintained drug exposure above the STAT3 IC50, with up to 60% reductions in STAT3-driven immune cell populations observed.
Chief Executive Officer Imran Alibhai characterized the results as demonstrating "substantially better tolerability" and expressed confidence in advancing TTI-109 into Phase 2 trials. He noted that the molecule holds promise for diseases currently served mainly by injected single-pathway therapies, particularly in dermatology and gastroenterology. However, the company cautioned that the data came from healthy volunteers, not patients, and that the pharmacodynamic effects were exploratory. New clinical programs for TTI-109 remain subject to Investigational New Drug (IND) clearance and additional funding.
The broader biotech sector also moved higher on Tuesday, though Tvardi's gains far outpaced the market. The SPDR S&P Biotech ETF (NYSEARCA: XBI) rose 2.1% to $164.13, while the iShares Biotechnology ETF (NASDAQ: IBB) gained 1.7% to $198.66. The strong relative performance underscores the market's focus on Tvardi's potential as an undervalued STAT3 play.
H.C. Wainwright analyst Sara Nik, who had previously set a $9 price target on Tvardi, reiterated her positive view, calling the stock a "discounted entry point" following the selloff after the failed IPF study. She highlighted that TTI-109 was specifically designed to address the tolerability limitations seen with TTI-101.
Despite the positive data, significant challenges remain. Tvardi's 10-Q filing for the period ending March 31 indicated that its capital resources would not fund planned operations for at least one year, raising substantial doubt about the company's ability to continue as a going concern. The company has no approved products for marketing and sale, and no product sales revenue. The company's July presentation lists Phase 1b/2 hepatocellular carcinoma topline data for TTI-101 expected in the second half of 2026, and a potential TTI-109 dermatology and/or gastroenterology study initiation in 2027, subject to IND clearance and funding.
